Reports Q2 revenue $15.8B, consensus $15.87B. “Earlier this month, we were pleased to announce our pending acquisition of Verona Pharma, which augments our portfolio and pipeline and is another example of acting decisively when science and value align,” said Robert M. Davis, chairman and chief executive officer. “Today, we announced a multiyear optimization initiative that will redirect investment and resources from more mature areas of our business to our burgeoning array of new growth drivers, further enable the transformation of our portfolio, and drive our next chapter of productive, innovation-driven growth. With these actions, I am confident that we are well positioned to generate near- and long-term value for our shareholders and, most importantly, deliver for our patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Trump administration mulls charging patent holders 1%-5% fee, WSJ reports
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, July 28 – August 01, 2025
- MRK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Six of top 20 pharma companies committed to Veeva Vault CRM, says Barclays